The Global Biosimilar Insulin Glargine Market was valued at USD 2046.40 Million in 2023 and is projected to reach USD 2623.79 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 2.80% during the forecast period (2023–2032). This growth is being driven by the escalating prevalence of diabetes worldwide, heightened demand for cost-effective treatment options, and expanding regulatory approvals for biosimilars that mimic the efficacy of originator insulin glargine products like Lantus. In North America, the market was estimated at USD 559.14 Million in 2023, with a projected CAGR of 2.40% from 2025 through 2032, fueled by advanced healthcare infrastructure and increasing adoption in managing type 1 and type 2 diabetes.
As the global healthcare sector shifts toward more accessible and sustainable diabetes management solutions, attention turns to the biosimilar developers leading the charge in innovation, affordability, and patient access. Biosimilar insulin glargine, a long-acting basal insulin analogue administered once daily to maintain steady blood sugar levels over 18 to 26 hours, is crucial for adults, adolescents, and children aged two and above with diabetes mellitus. In this blog, we profile the Top 10 Companies in the Biosimilar Insulin Glargine Industry—a diverse group of pharmaceutical leaders and biotech firms pioneering high-quality, lower-cost alternatives to branded insulins and transforming diabetes care globally.
🔟 1. Wockhardt Ltd.
Headquarters: Aurangabad, India
Key Offering: Biosimilar Insulin Glargine (Wosulin R, Wosulin N), Pre-filled pens and cartridges
Wockhardt is a prominent player in the biosimilars arena, with a strong focus on insulin products that offer reliable glycemic control for diabetes patients. The company’s biosimilar insulin glargine is designed to provide the same therapeutic benefits as the reference product, helping patients achieve stable blood glucose levels throughout the day. Wockhardt’s commitment to quality manufacturing and regulatory compliance has enabled it to expand its footprint in emerging markets, where diabetes rates are surging. Their products are particularly valued in hospital and retail pharmacy settings, supporting both type 1 and type 2 diabetes management.
Innovation and Access Initiatives:
- Investments in advanced bioprocessing to enhance production scalability
- Partnerships with global health organizations to improve insulin affordability in low-income regions
- Clinical trials demonstrating bioequivalence to originator products for broader approvals
Download FREE Sample Report: Biosimilar Insulin Glargine Market – View in Detailed Research Report
9️⃣ 2. Sandoz (Novartis Division)
Headquarters: Holzkirchen, Germany
Key Offering: Biosimilar Insulin Glargine (generic equivalents), Pre-filled syringes and cartridges
Sandoz, the generics and biosimilars arm of Novartis, has established itself as a key contributor to the biosimilar insulin glargine market by offering products that meet stringent regulatory standards in Europe and beyond. Their biosimilars provide a cost-effective option for basal insulin therapy, essential for long-term diabetes control. Operating through a robust supply chain, Sandoz serves hospitals, retail pharmacies, and other healthcare channels, emphasizing patient-centric delivery systems like user-friendly pens.
Innovation and Access Initiatives:
- Collaborations with regulatory bodies to expedite biosimilar approvals
- Programs aimed at reducing treatment costs through volume-based pricing
8️⃣ 3. Viatris Inc. (formerly Mylan)
Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Semglee (biosimilar insulin glargine), Pre-filled pens
Viatris has made significant strides in the U.S. and global markets with Semglee, its FDA-approved biosimilar insulin glargine that matches the efficacy and safety profile of the branded version. This product is particularly impactful in retail pharmacies, where it helps lower out-of-pocket costs for patients managing chronic diabetes. Viatris’s expertise in complex generics and biosimilars positions it well to address the growing need for affordable insulins amid rising healthcare expenses.
Innovation and Access Initiatives:
- Interchangeable designation for Semglee, allowing substitution at pharmacies
- Strategic alliances with payers to promote biosimilar adoption and cost savings
7️⃣ 4. Biocon Ltd.
Headquarters: Bangalore, India
Key Offering: Basalog (biosimilar insulin glargine), Cartridges and vials
Biocon is a biotech powerhouse driving the biosimilars revolution, with Basalog offering a high-quality alternative for basal insulin needs. Approved in multiple regions including India and Europe, Biocon’s product supports comprehensive diabetes care by providing consistent release of insulin microcrystals for extended action. The company focuses on emerging economies, where diabetes prevalence is high, and integrates its offerings into hospital protocols and community health programs.
Innovation and Access Initiatives:
- Goal to expand biosimilar portfolio to cover 20% of global insulin demand by 2030
- Local manufacturing initiatives to reduce costs and improve supply chain resilience
Download FREE Sample Report: Biosimilar Insulin Glargine Market – View in Detailed Research Report
6️⃣ 5. Geropharm JSC
Headquarters: Moscow, Russia
Key Offering: Biosimilar Insulin Glargine (Glarent), Pre-filled pens
Geropharm is a leading Russian pharmaceutical company specializing in insulin biosimilars, with Glarent providing effective long-acting control for diabetes patients across Eastern Europe and Central Asia. Their product is tailored to meet regional regulatory requirements and is distributed through hospitals and retail outlets. Geropharm emphasizes R&D to ensure bioequivalence and safety, contributing to accessible diabetes management in underserved areas.
Innovation and Access Initiatives:
- Certification of products under international standards for export potential
- Patient support programs to enhance adherence and education on insulin therapy
5️⃣ 6. Tonghua Dongbao Pharmaceutical Co., Ltd.
Headquarters: Tonghua, China
Key Offering: Ganlin (biosimilar insulin glargine), Pre-filled and cartridge formats
Tonghua Dongbao is a major force in Asia’s biosimilar market, with Ganlin offering a reliable once-daily basal insulin option that helps stabilize blood sugar in diverse patient populations. The company’s strong domestic presence in China, combined with exports to Southeast Asia, underscores its role in addressing the diabetes epidemic in high-burden regions. Ganlin is widely used in hospitals and pharmacies, supported by clinical data affirming its long-duration efficacy.
Innovation and Access Initiatives:
- Current production capacity exceeding 500,000 units annually
- Target to double market penetration in Asia-Pacific by 2027
4️⃣ 7. Shanghai United Laboratories Co., Ltd.
Headquarters: Shanghai, China
Key Offering: Biosimilar Insulin Glargine injections, Vials and pens
Shanghai United Laboratories plays a vital role in China’s burgeoning biosimilars sector, producing insulin glargine alternatives that facilitate better diabetes outcomes through consistent dosing. Their products are integral to national health initiatives aimed at controlling chronic diseases, serving a vast patient base via retail and institutional channels. The company’s focus on quality control ensures products meet global standards, fostering trust among healthcare providers.
Innovation and Access Initiatives:
- Limited but growing involvement in international partnerships for technology transfer
- R&D programs for next-generation delivery devices under national innovation frameworks
3️⃣ 8. Gan & Lee Pharmaceuticals Co., Ltd.
Headquarters: Beijing, China
Key Offering: Basalin (biosimilar insulin glargine), Pre-filled syringes
Gan & Lee is at the forefront of insulin innovation in China, with Basalin providing an affordable yet effective basal insulin for daily diabetes management. Approved by China’s NMPA and expanding to other markets, Basalin’s microcrystalline formulation ensures prolonged action, making it suitable for a wide age range of patients. The company supplies to hospitals and retail pharmacies, prioritizing supply stability in a high-demand environment.
Innovation and Access Initiatives:
- Indigenous research into recombinant DNA technology for cost reduction
- Collaborations with governments to scale production for public health programs
Download FREE Sample Report: Biosimilar Insulin Glargine Market – View in Detailed Research Report
2️⃣ 9. Eli Lilly and Company
Headquarters: Indianapolis, Indiana, USA
Key Offering: Basaglar (biosimilar insulin glargine), Pre-filled pens (KwikPen)
Eli Lilly co-developed Basaglar with Boehringer Ingelheim, marking one of the first insulin glargine biosimilars approved by the FDA. This product delivers the steady insulin release needed for effective basal coverage, interchangeable in many U.S. states to ease patient transitions from branded options. Lilly’s global distribution network ensures availability in hospitals, retail settings, and beyond, significantly impacting affordability for millions with diabetes.
Innovation and Access Initiatives:
- Aims to supply over 1 million units annually through expanded manufacturing
- Major initiatives for patient assistance and education on biosimilar benefits
1️⃣ 10. Samsung Bioepis Co., Ltd.
Headquarters: Incheon, South Korea
Key Offering: Biosimilar Insulin Glargine (Hagene), Cartridges and pens
Samsung Bioepis, a joint venture between Samsung and Biogen, leads in Asia with its biosimilar insulin glargine, offering seamless integration into diabetes regimens with proven safety and efficacy. Distributed across South Korea, Europe, and emerging markets, Hagene supports both hospital administrations and home use via convenient formats. The company’s biotech expertise drives continuous improvements in production and accessibility, making it a top player in global diabetes care.
Innovation and Access Initiatives:
- End-to-end solutions for biosimilar development and commercialization
- Strategic partnerships with EMA and FDA for accelerated market entry
Read Full Report: Biosimilar Insulin Glargine Market – View in Detailed Research Report
🌍 Outlook: The Future of Biosimilar Insulin Glargine Is More Accessible and Innovative
The biosimilar insulin glargine market is experiencing steady evolution. While originator products maintain a significant share, biosimilars are gaining traction through cost reductions of up to 30-50%, enhanced regulatory pathways, and increased awareness among healthcare providers. Investments in biomanufacturing and supply chains are key to meeting the demands of over 500 million people living with diabetes globally.
📈 Key Trends Shaping the Market:
- Rapid regulatory approvals in the EU, US, and Asia-Pacific regions
- Mandates for biosimilar adoption in national health policies by 2030
- Integration of digital tools for patient monitoring and insulin adherence
- Collaborations between biosimilar makers and diabetes advocacy groups
Market Trends Affecting Biosimilar Insulin Glargine Accessibility and Innovation
- Consolidation of Biosimilar Portfolios Under Major Pharma Groups — This simplifies development pipelines but demands careful attention to intellectual property and regional approvals. Recent mergers are redefining global distribution strategies.
- Adoption of Advanced Bioprocessing and Recombinant Technologies — Companies are shifting to more efficient manufacturing methods to lower costs and ensure supply stability, aligning with sustainability goals in healthcare. For instance, transitions to cell-line optimizations are enhancing yields.
- Digital Integration and Patient Support Platforms — Cloud-based systems for glucose tracking, dosage reminders, and telemedicine consultations (from partners like Lilly and Biocon) are becoming essential for multi-patient management in clinics and homes.
- User-Friendly Delivery Systems and Multi-Dose Formats — Pre-filled pens and smart injectors reduce administration errors and are preferred in retail and home settings. Leaders like Viatris continue to innovate here for better compliance.
- Automation in Production and Quality Control — Biotech firms are implementing robotic systems for filling and packaging to minimize contamination risks and scale output for high-demand markets like Asia.
Read Full Report: Biosimilar Insulin Glargine Market – View in Detailed Research Report
The companies listed above are not only delivering vital basal insulin therapies—they’re spearheading the global push for affordable diabetes management.